BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 26632437)

  • 1. Fingolimod ameliorates the development of experimental autoimmune encephalomyelitis by inhibiting Akt-mTOR axis in mice.
    Hou H; Cao R; Miao J; Sun Y; Liu X; Song X; Guo L
    Int Immunopharmacol; 2016 Jan; 30():171-178. PubMed ID: 26632437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapamycin and fingolimod modulate Treg/Th17 cells in experimental autoimmune encephalomyelitis by regulating the Akt-mTOR and MAPK/ERK pathways.
    Hou H; Cao R; Quan M; Sun Y; Sun H; Zhang J; Li B; Guo L; Song X
    J Neuroimmunol; 2018 Nov; 324():26-34. PubMed ID: 30205205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapamycin Ameliorates Experimental Autoimmune Encephalomyelitis by Suppressing the mTOR-STAT3 Pathway.
    Hou H; Miao J; Cao R; Han M; Sun Y; Liu X; Guo L
    Neurochem Res; 2017 Oct; 42(10):2831-2840. PubMed ID: 28600752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide.
    Colombo E; Di Dario M; Capitolo E; Chaabane L; Newcombe J; Martino G; Farina C
    Ann Neurol; 2014 Sep; 76(3):325-37. PubMed ID: 25043204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Target regulation of PI3K/Akt/mTOR pathway by cannabidiol in treatment of experimental multiple sclerosis.
    Giacoppo S; Pollastro F; Grassi G; Bramanti P; Mazzon E
    Fitoterapia; 2017 Jan; 116():77-84. PubMed ID: 27890794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fingolimod treatment promotes proliferation and differentiation of oligodendrocyte progenitor cells in mice with experimental autoimmune encephalomyelitis.
    Zhang J; Zhang ZG; Li Y; Ding X; Shang X; Lu M; Elias SB; Chopp M
    Neurobiol Dis; 2015 Apr; 76():57-66. PubMed ID: 25680941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dysregulation of sphingosine 1 phosphate receptor-1 (S1P1) signaling and regulatory lymphocyte-dependent immunosuppression in a model of post-fingolimod MS rebound.
    Cavone L; Felici R; Lapucci A; Buonvicino D; Pratesi S; Muzzi M; Hakiki B; Maggi L; Peruzzi B; Caporale R; Annunziato F; Amato MP; Chiarugi A
    Brain Behav Immun; 2015 Nov; 50():78-86. PubMed ID: 26130058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S1P
    Eken A; Duhen R; Singh AK; Fry M; Buckner JH; Kita M; Bettelli E; Oukka M
    Sci Rep; 2017 Oct; 7(1):12905. PubMed ID: 29018225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morpholino Analogues of Fingolimod as Novel and Selective S1P
    Stepanovska B; Zivkovic A; Enzmann G; Tietz S; Homann T; Kleuser B; Engelhardt B; Stark H; Huwiler A
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AKP-11 - A Novel S1P1 Agonist with Favorable Safety Profile Attenuates Experimental Autoimmune Encephalomyelitis in Rat Model of Multiple Sclerosis.
    Samuvel DJ; Saxena N; Dhindsa JS; Singh AK; Gill GS; Grobelny DW; Singh I
    PLoS One; 2015; 10(10):e0141781. PubMed ID: 26513477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Minocycline on Extracellular Matrix Metalloproteinase Inducer, a Factor Implicated in Multiple Sclerosis Immunopathogenesis.
    Hahn JN; Kaushik DK; Mishra MK; Wang J; Silva C; Yong VW
    J Immunol; 2016 Nov; 197(10):3850-3860. PubMed ID: 27733550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen receptor β ligand therapy activates PI3K/Akt/mTOR signaling in oligodendrocytes and promotes remyelination in a mouse model of multiple sclerosis.
    Kumar S; Patel R; Moore S; Crawford DK; Suwanna N; Mangiardi M; Tiwari-Woodruff SK
    Neurobiol Dis; 2013 Aug; 56():131-44. PubMed ID: 23603111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrine promotes oligodendrocyte development in CNS autoimmunity through the PI3K/Akt signaling pathway.
    Liu SQ; Zhang ML; Zhang HJ; Liu FZ; Chu RJ; Zhang GX; Zhu L
    Life Sci; 2017 Jul; 180():36-41. PubMed ID: 28499934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis.
    Rossi S; Lo Giudice T; De Chiara V; Musella A; Studer V; Motta C; Bernardi G; Martino G; Furlan R; Martorana A; Centonze D
    Br J Pharmacol; 2012 Feb; 165(4):861-9. PubMed ID: 21740406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fingolimod ameliorates chronic experimental autoimmune neuritis by modulating inflammatory cytokines and Akt/mTOR/NF-κB signaling.
    Feng Y; Feng F; Pan S; Zhang J; Li W
    Brain Behav; 2023 Apr; 13(4):e2965. PubMed ID: 36917739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple rodent models and behavioral measures reveal unexpected responses to FTY720 and DMF in experimental autoimmune encephalomyelitis.
    de Bruin NM; Schmitz K; Schiffmann S; Tafferner N; Schmidt M; Jordan H; Häußler A; Tegeder I; Geisslinger G; Parnham MJ
    Behav Brain Res; 2016 Mar; 300():160-74. PubMed ID: 26692368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
    Cohen JA; Chun J
    Ann Neurol; 2011 May; 69(5):759-77. PubMed ID: 21520239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel oxazolo-oxazole derivatives of FTY720 reduce endothelial cell permeability, immune cell chemotaxis and symptoms of experimental autoimmune encephalomyelitis in mice.
    Imeri F; Fallegger D; Zivkovic A; Schwalm S; Enzmann G; Blankenbach K; Meyer zu Heringdorf D; Homann T; Kleuser B; Pfeilschifter J; Engelhardt B; Stark H; Huwiler A
    Neuropharmacology; 2014 Oct; 85():314-27. PubMed ID: 24863045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mechanism of sesame oil in ameliorating experimental autoimmune encephalomyelitis in C57BL/6 mice.
    Ghazavi A; Mosayebi G
    Phytother Res; 2012 Jan; 26(1):34-8. PubMed ID: 21538630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ASP4058, a novel agonist for sphingosine 1-phosphate receptors 1 and 5, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile.
    Yamamoto R; Okada Y; Hirose J; Koshika T; Kawato Y; Maeda M; Saito R; Hattori K; Harada H; Nagasaka Y; Morokata T
    PLoS One; 2014; 9(10):e110819. PubMed ID: 25347187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.